Dr Reddy’s Labs launches Fulvestrant Injection, 250 mg/5 mL per Single-dose Syringe in US Market

Mumbai, Sep 8 (UNI) Pharma major Dr Reddy’s Labs announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe, a therapeutic equivalent generic version of Faslodex (fulvestrant) Injection, 250 mg/5 mL (50 mg/mL), approved by the US Food and Drug Administration (USFDA).
The Faslodex brand and generic market had U.S. sales of approximately USD407 million MAT for the most recent twelve months ending in June 2020, according to IQVIA Health.
Dr Reddy’s Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe is available in a carton containing two 5 mL single-dose prefilled syringes.
Faslodex is a trademark of the AstraZeneca group of companies.

LEAVE A REPLY

Please enter your comment!
Please enter your name here